(MENAFN- Swissinfo) Swiss pharmaceutical firm Roche has received approval from the US Food and Drug Administration (FDA) for its Elecsys pTau181 test capable of diagnosing Alzheimer's and other cognitive disorders through blood samples. This content was published on October 13, 2025 - 16:31 2 minutes Keystone-SDA

• Italiano it Roche, anche da USA via libera per test innovativo Alzheimer Original Read more: Roche, anche da USA via libera per test innovativo Alzheime

+ Get the most important news from Switzerland in your inbox

The test – developed by Roche in collaboration with the US pharmaceutical group Eli Lilly – is designed for patients aged 55 years and older with cognitive disorders or symptoms.

+ Weighing hope and hope with new Alzheimer's treatments

Elecsys pTau181 measures the blood concentration of the phosphorylated tau protein (pTau181), which is often elevated in the presence of Alzheimer's disease. In the case of non-significant values, the disease can be excluded with a high degree of probability.

The test can be performed in family doctors' offices, simplifies the diagnosis of the disease and helps determine whether a patient's cognitive decline is due to Alzheimer's or not.

It also saves costs associated with more invasive examinations. Currently, a computed tomography scan or analysis of cerebrospinal fluid by puncturing the spinal cord is required to obtain a clear diagnosis.

For its test, Roche had already obtained the CE mark of conformity last July for marketing the product on the European Union market.

More More Breakthrough Alzheimer's drug produced in Switzerland

This content was published on Jul 7, 2023 Biogen's new factory in Switzerland is the only producer of the active ingredient in Leqembi, approved to treat Alzheimer's disease.

Read more: Breakthrough Alzheimer's drug produced in Switzerlan

Translated from Italian with DeepL/mga

MENAFN13102025000210011054ID1110190334